Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis (ECHORTON)

August 23, 2021 updated by: University Hospital, Brest

Comparison of 2 Probes Frequencies in the Diagnosis of Giant Cell Arteritis

Evaluation of the structural features of temporal arteritis using two frequencies probes: 18 and 22Mhz.

Study Overview

Status

Completed

Conditions

Detailed Description

Comparison of the results obtained by using 2 different frequencies probes in the diagnosis of giant cell arteritis

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Brest, France, 29609
        • CHRU de Brest

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with suspicion of giant cell arteritis

Description

Inclusion Criteria:

  • sedimentation rate> 50 mm/h or recent unusual headache or unusual fever, recent visual trouble or jaw claudication, or induration temporal arteritis

Exclusion Criteria:

  • previous diagnosis of giant cell arteritis and relapse of the giant cell arteritis and opposition to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
halo sign of temporal arteritis
Time Frame: inclusion
hypoechogenicity of the wall artery
inclusion
compression sign of of temporal arteritis
Time Frame: inclusion
persistent of increased inflammatory arteries wall
inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
halo sign of carotid arteritis
Time Frame: inclusion
hypoechogenicity of the wall artery
inclusion
halo sign of subclavian arteritis
Time Frame: inclusion
hypoechogenicity of the wall artery
inclusion
halo sign of axillary arteritis
Time Frame: inclusion
hypoechogenicity of the wall artery
inclusion
other structural abnormalities in unilateral B mode
Time Frame: inclusion
stenosis, occlusion
inclusion
other structural abnormalities in bilateral B mode
Time Frame: inclusion
stenosis, occlusion
inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Brest

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 17, 2019

Primary Completion (ACTUAL)

August 24, 2020

Study Completion (ACTUAL)

August 24, 2020

Study Registration Dates

First Submitted

December 17, 2019

First Submitted That Met QC Criteria

December 17, 2019

First Posted (ACTUAL)

December 19, 2019

Study Record Updates

Last Update Posted (ACTUAL)

August 24, 2021

Last Update Submitted That Met QC Criteria

August 23, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ECHORTON (29BRC19.0275)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

Data will be available beginning 18 month and ending five years following the end of study

IPD Sharing Access Criteria

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Giant Cell Arteritis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe